Disturbance of activity and attention. Attention-deficit hyperactivity disorder, combined type
Conditions
Interventions
Intervention 1: Control group: Ritaline 10 to 30 mg per day and placebo as control group for 8 weeks. Intervention 2: Intervention group: Ritaline 10 to 30 mg per day and tipetidine 30 mg per day as
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
6 Years to 17 Years
Inclusion criteria
Inclusion criteria: Diagnosis of ADHD based on DSM-5 Age between 6-17 years old
Exclusion criteria
Exclusion criteria: Intellectual disability Presence of any psychiatric disorders except for ODD Receiving any neuroleptic during the last 6 months Weight less than 13.5 kg History of allergy to Tipeptidine or Ritaline Presence of any neurologic disease and any condition requiring surgery Uncontrolled seizures Systolic blood pressure more than 125 mm Hg; resting pulse rate less than 60/minute or more than 115/minute Severe medical disease Receiving any medication or supplement for treatment ADHD
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of ADHD. Timepoint: Week 0 (before treatment) and Weeks 4 and 8 after treatment. Method of measurement: Teacher and Parent ADHD Rating Scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactShahin Akhondzadeh
Tehran University of Medical Sciences
Outcome results
None listed